G Spagnoli
Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.
Lugli A, Terracciano L, Spagnoli G, Carafa V, Tornillo L, Mele V, Muraro M, Hostettler I, Iezzi G, Zlobec I. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010; 103:382-90.
Jul 6, 2010Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.
Jul 6, 2010Br J Cancer 2010; 103:382-90
Lugli Alessandro, Terracciano L, Spagnoli G, Carafa Vincenza, Tornillo Luigi, Mele V, Muraro M G, Hostettler Isabel, Iezzi Giandomenica, Zlobec Inti
Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients
Zajac P, Heberer M, Schultz-Thater E, Padovan E, Noppen C, Guller U, Bolli M, Adamina M, Marti W, Oertli D, Spagnoli G. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther 2003; 14:1497-510.
Nov 1, 2003Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients
Nov 1, 2003Hum Gene Ther 2003; 14:1497-510
Zajac P, Heberer M, Schultz-Thater E, Padovan E, Noppen C, Guller U, Bolli M, Adamina Michel, Marti W, Oertli D, Spagnoli G